Recommended procedure of the Czech Society of Hepatology for the diagnosis and treatment of acute porphyrias – update 2022

Česká verzia

Authors: Brůha R. ¹; Tomáš Fejfar ² ; Fraňková S. ³; Husová L. ^4,5; Husa P. ⁶; Hůlek P. ^2,7; Šperl J. ³; Urbánek P. ⁸; Vaňásek T. ²; Vítek L. ⁹
Authors place of work: IV. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze ¹; II. interní gastroenterologická klinika, FN Hradec Králové ²; Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha ³; Interní gastroenterologická klinika LF MU a FN Brno ⁴; Centrum kardiovaskulární a transplantační chirurgie Brno ⁵; Klinika infekčních chorob LF MU a FN Brno ⁶; Katedra interních oborů, LF OU a FN Ostrava ⁷; Interní klinika 1. LF UK a ÚVN Praha ⁸; IV. interní klinika a Ústav lékařské biochemie a laboratorní diagnostiky, 1. LF UK a VFN v Praze ⁹
Published in the journal: Gastroent Hepatol 2022; 76(2): 143-144
Category: Guidelines
doi: https://doi.org/10.48095/ccgh2022143

Zdroje

1. Fejfar T, Vaňásek T, Hůlek P et al. Primární biliární cholangitida – doporučený postup České hepatologické společnosti ČLS JEP pro diagnostiku a léčbu. Gastroent Hepatol 2018; 72 (2): 109–118. doi: 10.14735/amgh2018109.

2. Hirschfield GM, Mason A, Luketic V et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148 (4): 751–761. doi: 10.1053/j.gastro.2014.12.005.

3. Nevens F, Andreone P, Mazzella G et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375 (7): 631–643. doi: 10.1056/NEJMoa1509840.

4. Kowdley KV, Luketic V, Chapman R et al. Obeticholic Acid PBC Monotherapy Study Group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 2018; 67 (5): 1890–1902. doi: 10.1002/hep.29569.

5. Hirschfield GM, Beuers U, Corpechot C et al. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67 (1): 145–172. doi: 10.1016/j.jhep.2017.03.022.

6. Lindor KD, Bowlus CL, Boyer J et al. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 2022; 75 (4): 1012–1013. doi: 10.1002/hep.32117.

7. D’Amato D, De Vincentis A, Malinverno F et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep 2021; 3 (2): 100248. doi: 10.1016/ j.jhepr.2021.100248.

8. Trauner M, Nevens F, Shiffman ML et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol 2019; 4 (6): 445–453. doi: 10.1016/S2468-1253 (19) 30094-9.

9. Lindor KD, Bowlus CL, Boyer J et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69 (1): 394–419. doi: 10.1002/hep.30145.

10. Gideon M, Hirschfield GM, Dyson JK et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018; 67 (9): 1568–1594. doi: 10.1136/gutjnl-2017-315259.

11. National Institute for Health and Care Excellence. Obeticholic acid for treating primary biliary cholangitis. Technology appraisal guidance [TA443]. [online]. Dostupné z: https: //www.nice.org.uk/guidance/ta443/.

12. Harms MH, Hirschfield GM, Florean A et al. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Rep 2020; 3 (1): 100191. doi: 10.1016/ j.jhepr.2020.100191.